2 completed, 1 recruiting. 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Intas Pharmaceuticals, Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2) - Triple Negative Breast Cancer | Phase 3 | Recruiting | Jina Pharmaceuticals Inc. | 657 | 2018-07-10 | 2025-03-21 |
| Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects. INTP5, US Neulasta - Immunogenicity, Healthy Volunteers | Phase 1 | Completed | Intas Pharmaceuticals, Ltd. | 200 | 2018-02-26 | 2019-10-04 |
| Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects. INTP5, US Neulasta - Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers | Phase 1 | Completed | Intas Pharmaceuticals, Ltd. | 144 | 2018-02-12 | 2019-10-04 |
Triple Negative Breast Neoplasms (1)
Docetaxel (1)
India (3) · United States (1)
Vinu Jose, M.D. (2) · Adarsh K Garg, M.B.B.S (1) · Anshul Attrey, M.D. (1) · Dr. Ravi Alamchandani (1)